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Objectives
My goals for you at the end this lecture:
❖ Comfort in determining which transgender patients meet criteria for 
initiating CSH
❖ Appreciation of the overlap between transgender identity and psychiatric 
disease as mediated primarily by trauma
❖ Improved self efficacy in weighing risks/benefits of CSH therapy
❖ Familiarity with resources available to help support primary care 
providers take care of transgender patients 
Transgender Community Size
❖ 0.1-0.5% of global population1,2
❖ Estimated at 700,000 US persons3
❖ Isolated global examples exist:
➢ Fa’afafines (Samoa)
➢ Hijra (India)
1.Bye L, Gruskin E, Greenwood, G, Albright V, Krotki K. California Lesbians, Gays, Bisexuals, and Transgender (LGBT) Tobacco Use Survey – 2004. Sacramento, CA: California Department of Health Services, 2005.
2.Conron K, Scott G, Stowell G, Landers S. Transgender Health in Massachusetts: Results From a Household Probability Sample of Adults. Am J Public Health. 2012 January; 102(1): 118–122.
3.Gates GJ. How Many People Are Lesbian, Gay, Bisexual, and Transgender? Los Angeles, CA: Williams Institute, University of California, Los Angeles School of Law; 2011. Available at: http://www3.law.ucla.edu/ williamsinstitute/pdf/How-many-people-are-LGBTFinal.pdf. Accessed 
November 2015.
The Trans Community and Healthcare 
❖ Only 30-40% of transgender persons receive regular medical care4
❖ 19% had been refused medical care5
❖ 28% verbally harassed in medical setting5
❖ 2% physically assaulted in a physician’s office5
❖ 50% have had to teach their physician about transgender health5 
❖ Barriers: inability to access transgender friendly, and 
transgender-knowledgeable physicians4
4.Sanchez NF, Sanchez JP, Danoff A. Health Care Utilization, Barriers to Care, and Hormone Usage Among Male-to-Female Transgender Persons in New York City. American Journal of Public Health. 2009;99(4):713-719. 
5 Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M. Injustice at Every Turn: A Report of the National Transgender Discrimination Survey. Washington: National Center for Transgender Equality and National Gay and Lesbian Task Force, 2011
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Cases 1 & 2
D.H., a 22 y.o biological female seeking CSH
● Transidentity emerged in 9th grade
● “I am in the wrong body”
● Wanted to be on the baseball team 
instead of softball team
● Hates being penetrated during sex b/c 
reminder “that I have a vagina”
● Transitioned socially 2 years prior, has 
undergone legal name change, uses male 
pronouns in all aspects of life
● Has been seeing a gender therapist for 2 
years, hx of adjustment disorder, no 
other chronic psych/medical dx
A.D., a 34 y.o. biological male seeking CSH
● Since I was a toddler I “always knew I 
was not a boy but I did not know of an 
alternative”
● “At first I thought I was just gay” and 
came out as gay  to family yrs ago 
● Came out as trans to sister only 1 week 
prior
● Hx of drug abuse with multiple 
intentional overdoses
● Incarcerated (drug related)
● Succeeded in getting bachelor’s and 
planning to go to law school soon
● "I want to start hormones today” 
Interviewing Prior to Initiation of CSH therapy
● Emergence and persistence of transidentity?
● Goals of treatment (appear more masculine/feminine?, Top or bottom surgery?, androgynous 
appearance?)
● Social Support- Family? Friends? Work colleagues?
● Trauma history? (emotional, verbal, physical, sexual abuse)
● Psychiatric Hx? (hospitalizations, medications, SI/HI, attempts)
● History of prior gender affirming interventions (prescribed vs unprescribed meds, surgeries)?
● Employment, Food, Housing issues?
● Sexuality, and STD risks 
● Substance use? 
● Plans for fertility?
● Hx of preventative screenings especially sex organ screenings?
● Other medical problems?
Cases 1 & 2
D.H., a 22 y.o biological female seeking HRT
● Transidentity emerged in 9th grade
● “I am in the wrong body”
● Wanted to be on the baseball team 
instead of softball team
● Hates being penetrated during sex b/c 
reminder “that I have a vagina”
● Transitioned socially 2 years prior, has 
undergone legal name change, uses male 
pronouns in all aspects of life
● Has been seeing a gender therapist for 2 
years, hx of adjustment disorder, no 
other chronic psych/medical dx
A.D., a 34 y.o. biological male seeking HRT
● Since I was a toddler I “always knew I 
was not a boy but I did not know of an 
alternative”
● “At first I thought I was just gay” and 
came out as gay  to family yrs ago 
● Came out as trans to sister only 1 week 
prior
● Hx of drug abuse with multiple 
intentional overdoses
● Incarcerated (drug related)
● Succeeded in getting bachelor’s and 
planning to go to law school soon
● "I want to start hormones today” 
Cross Sex Hormones
❖ Estrogens (and androgen blockers) in people assigned to male sex at birth
❖ Androgens in people assigned to female sex at birth 
❖ Purpose: induce/maintain physical and physiological characteristics of sex 
that matches a person’s gender identity
❖ Not all trans people will take 
❖ Various protocols exist; no head to head trials comparing safety, efficacy
❖ Eg. 50mg once a week subcutaneously of testosterone cypionate
❖ Eg. 2mg BID of estradiol sublingually, and 50mg BID of spironolactone 
Selection of Appropriate Adult Patients for CSH 
WPATH Standards of Care, 7th Version
Criteria for Hormone Therapy
1. Persistent, well-documented gender dysphoria
2. Capacity to make a fully informed decision and to consent to treatment
3. Age of majority in a given country*
4. If significant medical or mental health concerns are present, they must be 
reasonably well controlled
6Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People 7th version. The World Professional Association for Transgender 
Health. 2011 <http://www.wpath.org>
Transgender  ≠ Gender Dysphoria
Cases 1 & 2
D.H., a 22 y.o biological female seeking HRT
● Transidentity emerged in 9th grade
● “I am in the wrong body”
● Wanted to be on the baseball team 
instead of softball team
● Hates being penetrated during sex b/c 
reminds him “that I have a vagina”
● Transitioned socially 2 years prior, has 
undergone legal name change, uses male 
pronouns in all aspects of life
● Has been seeing a gender therapist for 2 
years, hx of adjustment disorder, no 
other chronic psych/medical dx
A.D., a 34 y.o. biological male seeking HRT
● Since I was a toddler I “always knew I 
was not a boy” but did not know of an 
alternative
● At first thought “I was just gay” and 
came out to family yrs ago 
● Came out as trans to sister only 1 week 
prior
● Hx of drug abuse with multiple 
intentional overdoses
● Incarcerated (drug related)
● Succeeded in B.S. and planning to go to 
law school
● "I want to start hormones today” 
Case 1 Continued
D.H. was started on typical dose of testosterone cypionate (50mg SQ qweek)
1 month later seen in f/u and patient reports:
❖ “Change in voice”
❖ “Increased energy”
❖ “Slight increase in facial hair”
Requesting increase in testosterone dose to accelerate changes.
❖ Changes take years to be complete 
❖ Some changes are reversible, 
others are permanent
❖ Early, intermediate, late changes
7Taken from Cavanaugh, T, Hopwood, R, Gonzalez, A, Thompson, J. The medical care of transgender persons. Boston, MA: Fenway Health; 2015 Oct. 38 p. 
7Taken from Cavanaugh, T, Hopwood, R, Gonzalez, A, Thompson, J. The medical care of transgender persons. Boston, MA: Fenway Health; 2015 Oct. 38 p. 
❖ Changes take years to be complete 
❖ Some changes are reversible, 
others are permanent
❖ Goal is to achieve physiologic range 
of hormones
❖ Checking hormones can be 
particularly helpful if patient is not 
masculinizing/feminizing along 
expected time course
❖ Avoid supraphysiologic levels of 
hormones
7Taken from Cavanaugh, T, Hopwood, R, Gonzalez, A, Thompson, J. The medical care of transgender persons. Boston, MA: Fenway Health; 2015 Oct. 38 p. 
Cases 1&2 Summary
❖ Taking a transgender history 
❖ Criteria exist to help you determine patient appropriateness for CSH 
therapy
❖ Hormonal transition is a process that can take 2-3 years (or longer) to be 
complete
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Case 3
D.D., a 26 yo transgender male with psych hx of bipolar (stable for years) 
❖ 11/11/2016 - RN does patient teaching on self administration of T
❖ 11/15/2016 - pap smear visit
❖ 11/27/2016 - E.D. visit for increased anxiety, ran out of meds
❖ 11/30/2016 - clinic follow up
➢ New onset sexual interest & activity
➢ Notified therapist
➢ Agreed to closely follow
❖ 12/8/2016- hospitalized for acute mania
Mental Health & Transpersons
❖ The majority of transgender population does not have a clinically 
coexisting psychiatric condition!!!
❖ Still, transpersons at high risk for mood disorders, thought to be socially 
induced by transphobia (prejudice against transgender persons)
Transphobia 
Barriers to employment, 
education
Isolation/Rejection
Chronic 
Stress/Traumas 
Substance Abuse
Psychiatric Distress
Suicide Risk
Impact of CSH on Mental Health 
❖ Some evidence that access to gender affirming therapies can improve the 
quality of life and psychiatric symptomatology in transgender patients
➢ Better self esteem, mood after access to hormone therapy8
➢ Lower rates of self reported anxiety and depression9
➢ CSH associated with improved QoL and mental health but level of evidence low10
8. Gomez-Gil E, Zubiaurre-Elorza L, Esteva I, et al; Hormone-treated transsexuals report less social distress, anxiety, and depression. Psychoneuroendocrinology 2012; 37: 
662-670.
9. Colizzi M, Costa E, Todarello O.Transsexual patients' psychiatric comorbidity and positive effect of cross sex hormonal treatment on mental health: results from a 
longitudinal study. Psychoneuroendocrinology 2014; 39: 65-73.
10. White Hughto JM, Reisner SL. A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals. 
Transgender Health 2016; 1(1): 21-31.
Mental Health & Access to Gender Affirming Treatment
Barriers to employment, 
education
Isolation/Rejection
Chronic 
Stress/Traumas 
Substance Abuse
Psychiatric Disease
Suicide Risk
Transphobia
❖ Relief of gender dysphoria
What about testosterone?
❖ No clear evidence that testosterone 
precipitates mania
Outline
❖ Objectives
❖ Review of trans epidemiology 
❖ Healthcare and the Transcommunity
❖ Cases 1&2
➢ Taking a transgender History 
➢ CSH indications
❖ Case 3
➢ Mental Health and Transpersons
❖ Case 4
➢ Cardiovascular Risks and Estrogen in Transwomen
❖ Provider Resources
Case 4
M.D. is a 50 year old transgender woman with HTN and tbx dependence and 
with new onset of right lower extremity symptoms concerning for intermittent 
claudication. She has been on a regimen of 3mg BID of oral estradiol for many 
years. As part of her workup, she underwent a treadmill ABI, the results of 
which are significant for moderate to severe arterial occlusive disease of the 
bilateral lower extremities. Concerned, MD inquires whether this diagnosis 
requires her to stop taking estradiol.
Some Potential Side Effects of Estrogen Therapy
❖ Elevated blood pressure
❖ Decreased glucose tolerance
❖ Weight gain
❖ Increased triglycerides
Hormones, CVD risks in Transwomen
❖ Degree of cardiovascular risk posed by oral estrogen remains 
controversial 
❖ Subsequent studies of cisgender women contradictory conclusions about 
the risk of stroke and MI in postmenopausal women on HRT11
❖ Some evidence that transwomen on estrogen > CVD mortality than 
cismales12
❖ But, higher rates of smoking, HLD in transwomen compared to cisgender 
males confound evidence
❖ High quality RCTs on transwomen lacking 
Route of Estrogen & CVD risk 
❖ Switching from oral to a transdermal form of estrogen delivery may 
present a lower risk option 
❖ Studies in cisgender postmenopausal women that found no association of 
stroke with low doses of transdermal estrogen as compared with the 
elevated stroke risk seen with both low and high doses of oral 
estrogen13,14
❖ Unclear- may involve differential activation of the coagulation and/or 
inflammatory cascades?
Case 4 Conclusion
❖ Started on a regimen of aspirin 81mg, atorvastatin 40mg
❖ Referred to vascular surgery for further management
❖ Behavioral counseling for smoking cessation and daily exercise
❖ Switched to transdermal estrogen for continuation of her cross sex 
hormone therapy
Outline
❖ Objectives
❖ Review of trans epidemiology 
❖ Healthcare and the Transcommunity
❖ Cases 1&2
➢ Taking a transgender History 
➢ CSH indications
❖ Case 3
➢ Mental Health and Transpersons
❖ Case 4
➢ Cardiovascular Risks and Estrogen in Transwomen
❖ Provider Resources
Resources
❖ UCSF Center of Excellence for Transgender Health
➢ Guidelines for the Primary and Gender-Affirming Care of Transgender and 
Gender Nonbinary People, 2nd edition, July 2016
➢ http://transhealth.ucsf.edu/trans?page=guidelines-home
❖ Fenway Institute
➢ The Medical Care of Transgender Persons, Fall 2015
➢ http://fenwayhealth.org/
❖ Transline
➢ Free online medical consultation service
➢ http://project-health.org/transline/
❖ National Center for Transgender Equality
➢ www. transequality.org
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Thank you!
DSM-V
Gender Dysphoria in Adolescents and Adults
1. A marked incongruence between one’s experienced/expressed gender and assigned gender, of at least 6 months’ duration, as 
manifested by at least two of the following:
1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex 
characteristics (or in young adolescents, the anticipated secondary sex characteristics).
2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with 
one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated 
secondary sex characteristics).
3. A strong desire for the primary and/or secondary sex characteristics of the other gender.
4. A strong desire to be of the other gender (or some alternative gender different from one’s assigned gender).
5. A strong desire to be treated as the other gender (or some alternative gender different from one’s assigned gender).
6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender 
different from one’s assigned gender).
2. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of 
functioning.
"Gender Dysphoria." American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington: American Psychiatric Association, 2013.
 
